Tesamorelin

Tesamorelin is a synthetic form of human growth-hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid sequence stabilised by the addition of a trans-3-hexenoic acid group at the N-terminus, which protects against dipeptidyl peptidase IV (DPP-IV) cleavage and extends biological activity relative to native GHRH. This structural modification has made it a valuable pharmacological probe for studying endogenous GH axis stimulation through the GHRH receptor pathway.

Research with tesamorelin has focused on its ability to stimulate pulsatile GH release from somatotroph cells in a physiologically regulated manner — retaining the feedback-dependent suppression by somatostatin and IGF-1 that is absent with exogenous GH administration. This physiological regulation makes it an informative tool for studies seeking to preserve the normal architecture of the GH/IGF-1 axis while modulating its activity level.

Studies have used tesamorelin to investigate visceral adipose tissue dynamics, given documented relationships between GH secretion and lipolytic activity in visceral fat depots. Its well-characterised receptor pharmacology and predictable pulsatile secretion profile also make it useful as a reference GHRH analogue in comparative growth hormone secretagogue research.

For research purposes only. Not for human consumption.